Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56.1M
-
Number of holders
-
77
-
Total 13F shares, excl. options
-
22.8M
-
Shares change
-
+946K
-
Total reported value, excl. options
-
$956M
-
Value change
-
+$40.7M
-
Number of buys
-
49
-
Number of sells
-
-15
-
Price
-
$42.16
Significant Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q2 2020
81 filings reported holding BDTX - Black Diamond Therapeutics, Inc. - Common Stock as of Q2 2020.
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) has 77 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.8M shares
of 56.1M outstanding shares and own 40.57% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (3.45M shares), RA CAPITAL MANAGEMENT, L.P. (2.59M shares), BOXER CAPITAL, LLC (2.01M shares), Artal Group S.A. (1.55M shares), FMR LLC (1.42M shares), Bellevue Group AG (1.4M shares), WELLINGTON MANAGEMENT GROUP LLP (1.34M shares), PERCEPTIVE ADVISORS LLC (1.1M shares), VANGUARD GROUP INC (836K shares), and BlackRock Inc. (752K shares).
This table shows the top 77 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.